A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia; Schizophrenia and disorders with psychotic features
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Sep 2015 Top line results published in the Media Release.
    • 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top